Fig. 1From: Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in EuropeMean annual FIX treatment consumption and direct medical costs. EHL, extended half-life; IU, international units; SHL, short half-lifeBack to article page